검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Humira (adalimumab) | Stelara (ustekinumab) |
Overview Company | AbbVie | Janssen |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | IL-12 / IL-23 (p40) |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
MoA Mechanism | Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors | targeting IL-12 family signaling |
MoA Biomarker | biomarkers to support personalized treatment strategies | biomarkers but require external validation in independent cohorts |
PK/PD Half-life | — | 19 h |
PK/PD Species | Rat, xenografts, which corroborat | Cynomolgus monkey, NHP, Marmoset |
PK/PD Animal (cat.) | Rat | Human, NHP |
PK/PD Experiment | pharmacokinetic | pharmacokinetic |
Toxicology Species | Rat, xenografts, which corroborat | Cynomolgus monkey, NHP, Mouse, Marmoset |
Toxicology Animal (cat.) | Unknown | Mouse, NHP |
Toxicology Major finding | Interstitial lung disease, including pulmonary fibrosis, pulmonary embolism Skin reactions: Steve | — |
Clinical Primary efficacy | ORR 98.85% | ORR 75% |
Clinical PASI75 | — | 67% |
Clinical ORR | 98.85% | PASI75 ~67% (PsO pivotal) |
Clinical Result source | ClinicalTrials.gov NCT00427921 | PHOENIX |
Clinical Data Tier / Score | S · 92 | C · 91 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Humira (adalimumab) | Stelara (ustekinumab) |
Overview Company | AbbVie | Janssen |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | IL-12 / IL-23 (p40) |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
MoA Mechanism | Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors | targeting IL-12 family signaling |
MoA Biomarker | biomarkers to support personalized treatment strategies | biomarkers but require external validation in independent cohorts |
PK/PD Half-life | — | 19 h |
PK/PD Species | Rat, xenografts, which corroborat | Cynomolgus monkey, NHP, Marmoset |
PK/PD Animal (cat.) | Rat | Human, NHP |
PK/PD Experiment | pharmacokinetic | pharmacokinetic |
Toxicology Species | Rat, xenografts, which corroborat | Cynomolgus monkey, NHP, Mouse, Marmoset |
Toxicology Animal (cat.) | Unknown | Mouse, NHP |
Toxicology Major finding | Interstitial lung disease, including pulmonary fibrosis, pulmonary embolism Skin reactions: Steve | — |
Clinical Primary efficacy | ORR 98.85% | ORR 75% |
Clinical PASI75 | — | 67% |
Clinical ORR | 98.85% | PASI75 ~67% (PsO pivotal) |
Clinical Result source | ClinicalTrials.gov NCT00427921 | PHOENIX |
Clinical Data Tier / Score | S · 92 | C · 91 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교